報價延遲最少15分鐘:2026/06/21 11:22 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.39 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.35/-1.68
|
|
企業價值
164.99M
|
| 資產負債 |
|
每股賬面淨值
5.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
138.65M
|
|
每股收益
2.45
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific. |
